The Scientist

» Big Pharma and immunology

Most Recent

image: Bayer Enters CRISPR Field

Bayer Enters CRISPR Field

By | December 22, 2015

The pharmaceutical company will spend $335 million on a new venture with biotech startup CRISPR Therapeutics.

0 Comments

image: Pregnancy May Explain Ebola Return

Pregnancy May Explain Ebola Return

By | December 21, 2015

Health officials suspect recently reported cases of the disease in Liberia might stem from a flare-up of the virus in a survivor who became pregnant.

0 Comments

image: When the Flu Vax Fails

When the Flu Vax Fails

By | December 16, 2015

The status of a person’s immune system can predict when a seasonal flu vaccination will not provide sufficient protection, according to a study. 

0 Comments

image: Ebola’s Effects on the Eye

Ebola’s Effects on the Eye

By | November 30, 2015

A second doctor shows symptoms of ocular disease after recovering from Ebola infection.

0 Comments

image: Pfizer and Allergan to Merge

Pfizer and Allergan to Merge

By | November 23, 2015

The two drugmakers will join forces in a $160 billion deal—if it’s given the regulatory green light.

0 Comments

image: Birth of the Skin Microbiome

Birth of the Skin Microbiome

By | November 17, 2015

The immune system tolerates the colonization of commensal bacteria on the skin with the aid of regulatory T cells during the first few weeks of life, a mouse study shows.

0 Comments

image: Microbes Play Role in Anti-Tumor Response

Microbes Play Role in Anti-Tumor Response

By | November 5, 2015

Gut microbiome composition can influence the effectiveness of cancer immunotherapy in mice.

1 Comment

image: Ebola’s Immune Escape

Ebola’s Immune Escape

By | November 3, 2015

The virus can persist in several tissues where the immune system is less active. Researchers are working to better understand this phenomenon and how it can stall the clearing of Ebola in survivors.

1 Comment

image: Shire Buys Rare Disease Drug Developer

Shire Buys Rare Disease Drug Developer

By | November 2, 2015

The Irish drugmaker is set to acquire the Massachusetts-based Dyax in a $5.9 billion deal.

0 Comments

image: Fanning the Flames

Fanning the Flames

By | November 1, 2015

Obesity triggers a fatty acid synthesis pathway, which in turn helps drive T cell differentiation and inflammation.

0 Comments

Popular Now

  1. Henrietta Lacks’s Family Seeks Compensation
  2. Broad Wins CRISPR Patent Interference Case
    Daily News Broad Wins CRISPR Patent Interference Case

    The USPTO’s Patent Trial and Appeal Board has ruled in favor of the Broad Institute of MIT and Harvard retaining intellectual property rights covered by its patents for CRISPR gene-editing technology.

  3. Humans Never Stopped Evolving
    Features Humans Never Stopped Evolving

    The emergence of blood abnormalities, an adult ability to digest milk, and changes in our physical appearance point to the continued evolution of the human race.

  4. Abundant Sequence Errors in Public Databases
Business Birmingham